REQUEST A DEMO
Total
USD $0.00
Search more companies

Zentiva Pharma D.O.O. (Serbia)

Main Activities: Drugs and Druggists' Sundries Merchant Wholesalers
Full name: Zentiva Pharma D.O.O. Profile Updated: October 16, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English Download a sample report

Zentiva Pharma D.O.O. is based in Serbia. The head office is in Belgrade. It operates in the Drugs and Druggists' Sundries Merchant Wholesalers industry. There are currently 28 (2020) people employed by Zentiva Pharma D.O.O.. In 2023, the company reported a net sales revenue increase of 6.38%. Its total assets grew by 0.97% over the same period. Zentiva Pharma D.O.O.’s net profit margin increased by 1.21% in 2023.

Headquarters
Milentija Popovica 5 V
Belgrade; Belgrade; Postal Code: www.alvogen.com

Contact Details: Purchase the Zentiva Pharma D.O.O. report to view the information.

Website: http://CUBE_PROFILES_YU

Basic Information
Total Employees:
Purchase the Zentiva Pharma D.O.O. report to view the information.
Outstanding Shares:
Purchase the Zentiva Pharma D.O.O. report to view the information.
Registered Capital:
Purchase the Zentiva Pharma D.O.O. report to view the information.
Incorporation Date:
Key Executives
Purchase this report to view the information.
Director
Ownership Details
Purchase this report to view the information.
100%
Subsidiaries
Zentiva Pharma Makedonija D.O.O.E.L. (North Macedonia)
Company Performance
Financial values in the chart are available after Zentiva Pharma D.O.O. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency RSD. Absolute financial data is included in the purchased report.
Net sales revenue
6.38%
Total operating revenue
6.38%
Operating profit (EBIT)
42.93%
EBITDA
29.15%
Net Profit (Loss) for the Period
209.03%
Total assets
0.97%
Total equity
13.77%
Operating Profit Margin (ROS)
1.17%
Net Profit Margin
1.21%
Return on Equity (ROE)
7.66%
Debt to Equity Ratio
-58.84%
Quick Ratio
-0.22%
Cash Ratio
-0.15%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?